Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Keith Borkett"'
Autor:
Marija Pesic, Thomas Stöhr, Joachim Ossig, Keith Borkett, Martin Donsbach, Van-Anh Dao, Lynn Webster, Frank Schippers
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Abstract Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug cl
Externí odkaz:
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Autor:
Lynn R. Webster, Thomas Stohr, Martin Donsbach, Frank Schippers, Keith Borkett, Joachim Ossig, Marija Pesic, Van-Anh Dao
Publikováno v:
Drugs in R&D, Vol 20, Iss 3, Pp 267-277 (2020)
Drugs in R&D
Drugs in R&D
Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0207e8c27b0408874728bf10f48db05e
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
https://doaj.org/article/1d7e4135fdc34fe2a7679e3bb117e9d9
Autor:
Lynn R. Webster, Thomas Stoehr, Marija Pesic, Robert Saunders, Frank Schippers, Shawn L. Searle, Keith Borkett
Publikováno v:
Journal of Clinical Pharmacology
Remimazolam (RMZ) is a new and ultra‐fast‐acting, short‐duration intravenous benzodiazepine, a drug class associated with abuse potential. This trial was designed to compare the abuse potential of remimazolam with placebo and midazolam (MDZ), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37166b7d888077ffa4139d1445189160
https://doi.org/10.1002/jcph.1614
https://doi.org/10.1002/jcph.1614